North America Crispr And Cas Genes Market Size & Outlook
North America crispr and cas genes market, 2018-2030 (US$M)
Related Markets
North America crispr and cas genes market highlights
- The North America crispr and cas genes market generated a revenue of USD 1,937.6 million in 2024.
- The market is expected to grow at a CAGR of 15.7% from 2025 to 2030.
- In terms of segment, product was the largest revenue generating product & service in 2024.
- Service is the most lucrative product & service segment registering the fastest growth during the forecast period.
- Country-wise, Canada is expected to register the highest CAGR from 2025 to 2030.
North America data book summary
| Market revenue in 2024 | USD 1,937.6 million |
| Market revenue in 2030 | USD 4,610.0 million |
| Growth rate | 15.7% (CAGR from 2025 to 2030) |
| Largest segment | Product |
| Fastest growing segment | Service |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Product, Service |
| Key market players worldwide | AstraZeneca PLC, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, CRISPR Therapeutics AG, Editas Medicine Inc, Roche Holding AG, PerkinElmer, Genscript Biotech Corp Class H, Danaher Corp, Intellia Therapeutics Inc, Lonza Group Ltd, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc, Cibus Inc Ordinary Shares - Class A, Beam Therapeutics Inc, Vertex Pharmaceuticals Inc, Addgene, EGenesis, Synthego, Mammoth Biosciences, Inscripta, PLANTEDIT, Hera Biotech, Origene Technologies, Recombinetics |
Other key industry trends
- In terms of revenue, North America region accounted for 41.4% of the global crispr and cas genes market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 3,185.9 million by 2030.
Product was the largest segment with a revenue share of 87.77% in 2024. Horizon Databook has segmented the North America crispr and cas genes market based on product, service covering the revenue growth of each sub-segment from 2018 to 2030.
Continuous advanced biotechnological research in agriculture and a strong regional economy have resulted in North America’s leading share in the global market. The presence of several government initiatives in the U.S. and Canada supports biotechnological research in agriculture and introduction of CRISPR based plant products.
Moreover, several pharmaceuticals and seed companies are investing in growth strategies, such as acquisitions, partnerships, and collaborations, to boost the market for pharmaceuticals & plant breeding, which can help boost the demand for CRISPR technologies in these industries.
For instance, in June 2019, Vertex Pharmaceuticals stated that it planned to expand its presence in gene editing by developing novel treatments for Myotonic Dystrophy Type 1 and Duchenne Muscular Dystrophy.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
CRISPR And Cas Genes Market Scope
CRISPR And Cas Genes Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America crispr and cas genes market size, by country, 2018-2030 (US$M)
North America CRISPR And Cas Genes Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
